PROTEIN SYNTHESIS INHIBITOR
Synribo is a prescription medication approved by the Food and Drug Administration (FDA) to treat adults with chronic myeloid leukemia (CML) in the chronic or accelerated phase. Synribo is indicated in cases where two tyrosine kinase inhibitors have failed or could not be tolerated. Synribo may also be referred to by its drug name, Omacetaxine mepesuccinate.
Synribo is the first drug in a new class called protein synthesis inhibitors. Synribo is believed to work by interfering with proteins in leukemia cells, causing them to die.
How do I take it?
Synribo is administered by subcutaneous injection over several days of a 28-day cycle.
Synribo comes in the form of a single-dose vial.
The FDA-approved label for Synribo lists common side effects including fatigue, weakness, fever, injection site reactions, nausea, diarrhea, and low blood cell counts.
Rare but serious side effects listed for Synribo include high blood glucose, fetal harm in pregnant women, and severe bleeding that can include life-threatening bleeds in the brain or gastrointestinal system.
For more details about this treatment, visit:
Synribo – Cephalon
CML: Relapsed and Refractory – Leukemia and Lymphoma Society